Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Zevra Therapeutics (ZVRA) over the last 9 years, with Q3 2025 value amounting to 15.87%.

  • Zevra Therapeutics' EBITDA Margin rose 7538700.0% to 15.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 103.86%, marking a year-over-year increase of 2502800.0%. This contributed to the annual value of 368.47% for FY2024, which is 1878400.0% down from last year.
  • Zevra Therapeutics' EBITDA Margin amounted to 15.87% in Q3 2025, which was up 7538700.0% from 274.28% recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' EBITDA Margin ranged from a high of 57.44% in Q1 2021 and a low of 1908.85% during Q2 2022
  • Its 5-year average for EBITDA Margin is 324.71%, with a median of 128.34% in 2024.
  • Per our database at Business Quant, Zevra Therapeutics' EBITDA Margin tumbled by -19575100bps in 2022 and then surged by 18350300bps in 2023.
  • Zevra Therapeutics' EBITDA Margin (Quarter) stood at 110.07% in 2021, then crashed by -311bps to 452.13% in 2022, then surged by 74bps to 117.31% in 2023, then dropped by -9bps to 128.34% in 2024, then surged by 112bps to 15.87% in 2025.
  • Its EBITDA Margin was 15.87% in Q3 2025, compared to 274.28% in Q2 2025 and 26.28% in Q1 2025.